Jim Tananbaum with over 25 years of experience in investing and building healthcare companies, is a CEO and founder of Foresite Capital a healthcare growth equity firm based in San Francisco with an office to in New York. Jim’s other major investments include Amira Pharmaceuticals, Healtheon, among others. He holds a B.S.E.E. from Yale University, an MD from Harvard Medical School not forgetting an MBA in business from Harvard Business School.
According to the release from Biz Journals, 2017 Midas list, Jim Tananbaum appears among the top one hundred investors. It reveals that it is hard for a venture capital investor to stay on top of their game as these calls for the risk taking, calculations, and being lucky.In order to rank and achieve a deal metric ranking against competing investors, a summed score, which determines the ranking for each VC is determined too.
Put together, the rankings from a transaction parameter and deal count score, are reviewed by experienced investors and experts. By so doing this is used to determine a venture capitalist’s position on The Midas List. As for Jim’s appearance on the Midas list is a light show that Jim Tananbaum has the qualities to be a top investor.
Furthermore, Forest site capital health care has hit the headlines of San Francisco Business Wire through the press release that published the ability of it to hire Dr. Molly He as a venture partner who happens to be former and worked as the senior director at Illumina. He also worked for 15 years in Genomic and Pharmaceutical research and development. Jim termed Dr. He as a respected scientific researcher in the area of next-generation sequencing and her presence on the board is welcomed by his team.
Foresite Capital is focused on providing a platform to both the private and public markets through growth capital to emerging healthcare leaders with unstable products and services in other healthcare sectors. For over the last 20years, Dr. Jim has founded and given a hand to the growth of healthcare franchises in parts of the healthcare’s economy. Jim Tananbaum is also a co-founder of GelTex Pharmaceuticals, which brought into the market two drugs, being later sold for $1.6 billion.